Skip to main content

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the first quarter ended July 31, 2022, on Thursday, September 8, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 618777. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46511, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/714836/Champions-Oncology-to-Announce-First-Quarter-Financial-Results-on-Thursday-September-8-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  200.39
+1.60 (0.80%)
AAPL  259.92
+4.14 (1.62%)
AMD  198.27
-9.05 (-4.37%)
BAC  53.04
+0.49 (0.93%)
GOOG  299.71
-6.31 (-2.06%)
META  633.38
-6.39 (-1.00%)
MSFT  397.69
-3.63 (-0.91%)
NVDA  181.27
-1.54 (-0.84%)
ORCL  154.08
-6.06 (-3.78%)
TSLA  404.33
-13.11 (-3.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.